<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536601</url>
  </required_header>
  <id_info>
    <org_study_id>I 72806</org_study_id>
    <secondary_id>NCI-2011-00131</secondary_id>
    <secondary_id>I 72806</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT00536601</nct_id>
  </id_info>
  <brief_title>High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors</brief_title>
  <official_title>Autologous Blood and Marrow Transplantation for Hematologic Malignancies and Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial studies different high-dose chemotherapy regimens with or without total-body&#xD;
      irradiation (TBI) to compare how well they work when given before autologous stem cell&#xD;
      transplant (ASCT) in treating patients with hematologic cancer or solid tumors. Giving&#xD;
      high-dose chemotherapy with or without TBI before ASCT stops the growth of cancer cells by&#xD;
      stopping them from dividing or killing them. After treatment, stem cells are collected from&#xD;
      the patient's blood or bone marrow and stored. More chemotherapy may be given to prepare for&#xD;
      the stem cell transplant. The stem cells are then returned to the patient to replace the&#xD;
      blood forming cells that were destroyed by the chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Estimate the progression free survival (PFS) distribution for Hodgkin lymphoma (HL),&#xD;
      non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) for each disease-specific high dose&#xD;
      therapy regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Estimate the PFS distribution for amyloidosis, acute leukemia and selected solid tumors&#xD;
      for each disease-specific high dose therapy regimen.&#xD;
&#xD;
      II. Explore the role of risk factors in the outcome of all treated patients. III. Examine the&#xD;
      high dose therapy regimen-related toxicity (RRT) and overall survival after bone marrow&#xD;
      transplant (BMT).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients are assigned to conditioning regimens based on disease, age, and co-morbidities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2006</start_date>
  <completion_date type="Actual">July 9, 2018</completion_date>
  <primary_completion_date type="Actual">July 9, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)</measure>
    <time_frame>From the date of transplantation to the date of first observed disease progression or death due to any cause, assessed up to 12 years</time_frame>
    <description>Assessed using the product-limit based Kaplan Meier method. Additionally, a 95% confidence interval of the distribution will be computed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal))</measure>
    <time_frame>Up to 100 days after transplantation</time_frame>
    <description>Toxicities will be reported using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (Complete Remission)</measure>
    <time_frame>At 100 days</time_frame>
    <description>Response rates will be reported using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, Presented as the Estimate at 10-yrs (Median Follow-up Time in Survivors)</measure>
    <time_frame>Patients are followed up to maximum of 12 years</time_frame>
    <description>Assessed using the product-limit based Kaplan Meier method.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Burkitt Lymphoma</condition>
  <condition>Childhood Diffuse Large Cell Lymphoma</condition>
  <condition>Childhood Immunoblastic Large Cell Lymphoma</condition>
  <condition>Childhood Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Hepatosplenic T-cell Lymphoma</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Peripheral T-cell Lymphoma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <condition>Primary Systemic Amyloidosis</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Malignant Testicular Germ Cell Tumor</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Regional Neuroblastoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Testicular Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Regimen CBV (patients with HL or NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etoposide intravenously (IV) continuously over 34 hours on day -8, cyclophosphamide IV over 2 hours on days -7 to -4, and carmustine IV over 2 hours on day -3. Patients undergo ASCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen M200/M120 (patients with MM or amyloidosis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 200 or 120 mg/m^2 of melphalan IV over 30 minutes on day -2. Patients undergo ASCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen BuC2iv (patients with ALL, AML, HL, or NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV over 2 hours then every 6 hours on days -7 to -4 for 16 total doses and cyclophosphamide IV over 2 hours on days -3 and -2. Patients undergo ASCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen CT6 (patients with ALL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 2 hours on days -5 to -4. Patients then undergo TBI twice daily on days -3 to -1. Patients undergo ASCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen CTtCp (patients with other solid tumors)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV continuously, carboplatin IV continuously, and thiotepa IV continuously over 24 hours on days -7 to -4. Patients undergo ASCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen VCp (patients with testicular cancer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients then undergo a second ASCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen TtC1500/ECpM (patients with NBL or SRBCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 2 hours on days -5 to -2. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive carboplatin IV continuously over 24 hours on days -7 to -4, etoposide IV continuously over 24 hours on days -7 to -4, and melphalan IV over 30 minutes on days -7 to -5. Patients undergo a second ASCT on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen CBV (patients with HL or NHL)</arm_group_label>
    <arm_group_label>Regimen TtC1500/ECpM (patients with NBL or SRBCT)</arm_group_label>
    <arm_group_label>Regimen VCp (patients with testicular cancer)</arm_group_label>
    <other_name>EPEG</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen BuC2iv (patients with ALL, AML, HL, or NHL)</arm_group_label>
    <arm_group_label>Regimen CBV (patients with HL or NHL)</arm_group_label>
    <arm_group_label>Regimen CT6 (patients with ALL)</arm_group_label>
    <arm_group_label>Regimen CTtCp (patients with other solid tumors)</arm_group_label>
    <arm_group_label>Regimen TtC1500/ECpM (patients with NBL or SRBCT)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen CBV (patients with HL or NHL)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>BiCNU</other_name>
    <other_name>bis-chloronitrosourea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen M200/M120 (patients with MM or amyloidosis)</arm_group_label>
    <arm_group_label>Regimen TtC1500/ECpM (patients with NBL or SRBCT)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen BuC2iv (patients with ALL, AML, HL, or NHL)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen CTtCp (patients with other solid tumors)</arm_group_label>
    <arm_group_label>Regimen TtC1500/ECpM (patients with NBL or SRBCT)</arm_group_label>
    <arm_group_label>Regimen VCp (patients with testicular cancer)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen CTtCp (patients with other solid tumors)</arm_group_label>
    <arm_group_label>Regimen TtC1500/ECpM (patients with NBL or SRBCT)</arm_group_label>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>TSPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Regimen CT6 (patients with ALL)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo ASCT</description>
    <arm_group_label>Regimen BuC2iv (patients with ALL, AML, HL, or NHL)</arm_group_label>
    <arm_group_label>Regimen CBV (patients with HL or NHL)</arm_group_label>
    <arm_group_label>Regimen CT6 (patients with ALL)</arm_group_label>
    <arm_group_label>Regimen CTtCp (patients with other solid tumors)</arm_group_label>
    <arm_group_label>Regimen M200/M120 (patients with MM or amyloidosis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous-autologous tandem hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo tandem ASCT</description>
    <arm_group_label>Regimen TtC1500/ECpM (patients with NBL or SRBCT)</arm_group_label>
    <arm_group_label>Regimen VCp (patients with testicular cancer)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of malignant hematologic disorders, amyloidosis or&#xD;
             solid tumor malignancy&#xD;
&#xD;
          -  Recurrent or refractory disease or disease at high risk for recurrence&#xD;
&#xD;
          -  Hodgkin Disease (HL): Relapsed or refractory disease after chemotherapy with a minimum&#xD;
             of one standard regimen&#xD;
&#xD;
          -  Non-Hodgkin Lymphoma (NHL): (Low, Intermediate or High Grade) Relapsed or refractory&#xD;
             disease after chemotherapy with at least one standard regimen or first complete&#xD;
             remission (CR) lymphoblastic or small, non-cleaved cell lymphoma at high risk of&#xD;
             relapse by high International Prognostic Index (IPI) Score&#xD;
&#xD;
          -  Acute Myeloid Leukemia (AML): Low or High Risk disease in first or second CR or&#xD;
             greater in patients in whom the risks of an allogeneic transplant outweigh the&#xD;
             benefits&#xD;
&#xD;
          -  Acute Lymphoblastic Leukemia (ALL): Low or high risk disease in first or second CR in&#xD;
             whom the risks of an allogeneic transplant outweigh the benefits&#xD;
&#xD;
          -  Multiple Myeloma (MM): Low or high risk in first or greater response (stable disease&#xD;
             or better) or for responding patients at first progression&#xD;
&#xD;
          -  Other Malignant Lymphoproliferative Disorders: (chronic lymphocytic lymphoma [CLL],&#xD;
             Waldenstroms macroglobulinemia, relapsed or refractory disease after first-line&#xD;
             chemotherapy&#xD;
&#xD;
          -  Amyloidosis: primary or previously treated&#xD;
&#xD;
          -  Solid Tumors: Testicular cancer patients who have relapsed disease or primary&#xD;
             progressive disease which is responding to salvage therapy; relapsed or advanced-stage&#xD;
             newly diagnosed neuroblastoma (NBL) or small round blue cell tumors (SRBCT) in&#xD;
             patients 30 years of age; other patients with solid tumors who have recurred following&#xD;
             conventional treatment or are at high risk for relapse, and demonstrate&#xD;
             chemosensitivity&#xD;
&#xD;
          -  Patients with malignancies who would be treated with an autologous stem cell&#xD;
             transplant but have a syngeneic donor; a syngeneic donor would be considered to have&#xD;
             the same risk as an autologous stem cell transplant patient&#xD;
&#xD;
          -  Performance status 0-2 (Karnofsky performance status [KPS] &gt;= 70%); patients with&#xD;
             amyloidosis or MM with decreased KPS due to disease are eligible&#xD;
&#xD;
          -  Life expectancy &gt; 2 months&#xD;
&#xD;
          -  Pulmonary function tests; diffusing capacity of the lung for carbon monoxide (DLCO) or&#xD;
             diffusing volume of the alveolar volume (DLVA) &gt;= 50% predicted; DLCO to be corrected&#xD;
             for hemoglobin and/or alveolar ventilation&#xD;
&#xD;
          -  Cardiac ventricular ejection fraction &gt;= 50% by radionuclide ventriculogram or&#xD;
             echocardiogram&#xD;
&#xD;
          -  Bilirubin &lt; 3 x normal&#xD;
&#xD;
          -  Alkaline phosphatase, serum glutamic oxaloacetic transaminase (SGOT) &lt; 3 x normal&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 40 cc/min by the modified Cockcroft-Gault formula&#xD;
             for adults or the Schwartz formula for pediatrics&#xD;
&#xD;
          -  Glomerular filtration rate by renal scan for neuroblastoma patients, to determine&#xD;
             dosing parameters&#xD;
&#xD;
          -  Positive cytomegalovirus (CMV) immunoglobulin M (IgM) and/or positive hepatitis&#xD;
             serologies demonstrating infection will require an Infectious Disease consult and&#xD;
             subsequent clearance&#xD;
&#xD;
          -  Any active infection will require an Infectious Disease consult and subsequent&#xD;
             clearance&#xD;
&#xD;
          -  Peripheral Blood Counts of polymorphonuclear neutrophil (PMN) &gt; 1500/uL&#xD;
&#xD;
          -  Platelet (Plt) &gt; 75,000/uL&#xD;
&#xD;
          -  Prior to stem cell storage:&#xD;
&#xD;
               -  No radiation within three weeks before stem cell harvest&#xD;
&#xD;
               -  Bone marrow may be used in conjunction with blood progenitor cells&#xD;
&#xD;
          -  Hematologic Malignancy patients with human immunodeficiency virus (HIV) positivity but&#xD;
             on appropriate anti-retroviral therapy may go autotransplant with the following&#xD;
             laboratory tests; (CD4+ cell count &gt; 75 cells per microliter and HIV copy number &lt;&#xD;
             100,000 per microliter and with Infectious Disease clearance&#xD;
&#xD;
          -  Acute Leukemia, HL, NHL, MM and Solid Tumor patients must have received 2 cycles of&#xD;
             chemotherapy followed by disease-specific restaging prior to mobilization and&#xD;
             collection of stem cells; small round blue cell tumor patients must have received&#xD;
             either standard therapy or surgical intervention; the disease status and response to&#xD;
             therapy must be known prior to transplant to establish the disease status at&#xD;
             transplant; amyloidosis patients may proceed to BMT without receiving chemotherapy&#xD;
&#xD;
          -  No serious organ dysfunction unless it is caused by the underlying disease, exclusion&#xD;
             criteria include the following:&#xD;
&#xD;
               -  Uncontrolled or severe cardiovascular disease, including recent (&lt; 6 months)&#xD;
                  myocardial infarction, congestive heart failure, symptomatic angina,&#xD;
                  life-threatening arrhythmia or hypertension&#xD;
&#xD;
               -  Active bacterial, viral, or fungal infection&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No serious medical or psychiatric illness&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No psychiatric conditions which would prevent delivery of care; psychology clearance&#xD;
             is necessary&#xD;
&#xD;
          -  Allogeneic BMT not possible, or not desirable&#xD;
&#xD;
               -  Age &gt; 65 years&#xD;
&#xD;
               -  No compatible donor identified&#xD;
&#xD;
               -  Estimated risk of graft vs. host disease complications greater than risk of&#xD;
                  recurrence after autologous BMT&#xD;
&#xD;
          -  Adequate bone marrow or blood stem cell dose obtained:&#xD;
&#xD;
               -  For blood stem cells: total CD 34+ &gt;= 2 x 10^6/kg or if unable to collect this&#xD;
                  dose, a total nucleated cell bone marrow dose of &gt;= l x 10^8/kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip McCarthy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <results_first_submitted>March 23, 2021</results_first_submitted>
  <results_first_submitted_qc>March 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2021</results_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT00536601/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acute Leukemia</title>
          <description>Patients diagnosed with and treated for acute myeloid leukemia or acute lymphoblastic leukemia</description>
        </group>
        <group group_id="P2">
          <title>Hodgkin Lymphoma</title>
          <description>Patients diagnosed with and treated for Hodgkin Lymphoma</description>
        </group>
        <group group_id="P3">
          <title>Non-Hodgkin Lymphoma</title>
          <description>Patients diagnosed with and treated for Non-Hodgkin Lymphoma</description>
        </group>
        <group group_id="P4">
          <title>MM/Amyloid</title>
          <description>Patients diagnosed with or treated for multiple myeloma or amyloidosis</description>
        </group>
        <group group_id="P5">
          <title>Solid Tumors</title>
          <description>Patients diagnosed with and treated for a solid tumor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients enrolled on study and stratified by disease group as defined in statistical analysis section of protocol</population>
      <group_list>
        <group group_id="B1">
          <title>Acute Leukemia</title>
          <description>Patients diagnosed with and treated for acute myeloid leukemia or acute lymphoblastic leukemia</description>
        </group>
        <group group_id="B2">
          <title>Hodgkin Lymphoma</title>
          <description>Patients diagnosed with and treated for Hodgkin Lymphoma</description>
        </group>
        <group group_id="B3">
          <title>Non-Hodgkin Lymphoma</title>
          <description>Patients diagnosed with and treated for Non-Hodgkin Lymphoma</description>
        </group>
        <group group_id="B4">
          <title>MM/Amyloid</title>
          <description>Patients diagnosed with or treated for multiple myeloma or amyloidosis</description>
        </group>
        <group group_id="B5">
          <title>Solid Tumors</title>
          <description>Patients diagnosed with and treated for a solid tumor</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="159"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk Group</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>High</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Standard</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)</title>
        <description>Assessed using the product-limit based Kaplan Meier method. Additionally, a 95% confidence interval of the distribution will be computed.</description>
        <time_frame>From the date of transplantation to the date of first observed disease progression or death due to any cause, assessed up to 12 years</time_frame>
        <population>Each disease strata presents PFS for each conditioning regimen defined in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Leukemia</title>
            <description>Patients diagnosed with and treated for acute myeloid leukemia or acute lymphoblastic leukemia</description>
          </group>
          <group group_id="O2">
            <title>Hodgkin Lymphoma</title>
            <description>Patients diagnosed with and treated for Hodgkin Lymphoma</description>
          </group>
          <group group_id="O3">
            <title>Non-Hodgkin Lymphoma</title>
            <description>Patients diagnosed with and treated for Non-Hodgkin Lymphoma</description>
          </group>
          <group group_id="O4">
            <title>MM/Amyloid</title>
            <description>Patients diagnosed with or treated for multiple myeloma or amyloidosis</description>
          </group>
          <group group_id="O5">
            <title>Solid Tumors</title>
            <description>Patients diagnosed with and treated for a solid tumor</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)</title>
          <description>Assessed using the product-limit based Kaplan Meier method. Additionally, a 95% confidence interval of the distribution will be computed.</description>
          <population>Each disease strata presents PFS for each conditioning regimen defined in the protocol</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BuCy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="0" upper_limit="71"/>
                    <measurement group_id="O2" value="14" lower_limit="0" upper_limit="40"/>
                    <measurement group_id="O3" value="22" lower_limit="7" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CBV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="43" lower_limit="17" upper_limit="69"/>
                    <measurement group_id="O3" value="37" lower_limit="23" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VCp</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="43" lower_limit="6" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mel120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="22" lower_limit="2" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mel200</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="13" lower_limit="3" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CyTtCp</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TtC1500</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="50" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal))</title>
        <description>Toxicities will be reported using descriptive statistics.</description>
        <time_frame>Up to 100 days after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Leukemia</title>
            <description>Patients diagnosed with and treated for acute myeloid leukemia or acute lymphoblastic leukemia</description>
          </group>
          <group group_id="O2">
            <title>Hodgkin Lymphoma</title>
            <description>Patients diagnosed with and treated for Hodgkin Lymphoma</description>
          </group>
          <group group_id="O3">
            <title>Non-Hodgkin Lymphoma</title>
            <description>Patients diagnosed with and treated for Non-Hodgkin Lymphoma</description>
          </group>
          <group group_id="O4">
            <title>MM/Amyloid</title>
            <description>Patients diagnosed with or treated for multiple myeloma or amyloidosis</description>
          </group>
          <group group_id="O5">
            <title>Solid Tumors</title>
            <description>Patients diagnosed with and treated for a solid tumor</description>
          </group>
        </group_list>
        <measure>
          <title>Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal))</title>
          <description>Toxicities will be reported using descriptive statistics.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (Complete Remission)</title>
        <description>Response rates will be reported using descriptive statistics.</description>
        <time_frame>At 100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Leukemia</title>
            <description>Patients diagnosed with and treated for acute myeloid leukemia or acute lymphoblastic leukemia</description>
          </group>
          <group group_id="O2">
            <title>Hodgkin Lymphoma</title>
            <description>Patients diagnosed with and treated for Hodgkin Lymphoma</description>
          </group>
          <group group_id="O3">
            <title>Non-Hodgkin Lymphoma</title>
            <description>Patients diagnosed with and treated for Non-Hodgkin Lymphoma</description>
          </group>
          <group group_id="O4">
            <title>MM/Amyloid</title>
            <description>Patients diagnosed with or treated for multiple myeloma or amyloidosis</description>
          </group>
          <group group_id="O5">
            <title>Solid Tumors</title>
            <description>Patients diagnosed with and treated for a solid tumor</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Complete Remission)</title>
          <description>Response rates will be reported using descriptive statistics.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival, Presented as the Estimate at 10-yrs (Median Follow-up Time in Survivors)</title>
        <description>Assessed using the product-limit based Kaplan Meier method.</description>
        <time_frame>Patients are followed up to maximum of 12 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Leukemia</title>
            <description>Patients diagnosed with and treated for acute myeloid leukemia or acute lymphoblastic leukemia</description>
          </group>
          <group group_id="O2">
            <title>Hodgkin Lymphoma</title>
            <description>Patients diagnosed with and treated for Hodgkin Lymphoma</description>
          </group>
          <group group_id="O3">
            <title>Non-Hodgkin Lymphoma</title>
            <description>Patients diagnosed with and treated for Non-Hodgkin Lymphoma</description>
          </group>
          <group group_id="O4">
            <title>MM/Amyloid</title>
            <description>Patients diagnosed with or treated for multiple myeloma or amyloidosis</description>
          </group>
          <group group_id="O5">
            <title>Solid Tumors</title>
            <description>Patients diagnosed with and treated for a solid tumor</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival, Presented as the Estimate at 10-yrs (Median Follow-up Time in Survivors)</title>
          <description>Assessed using the product-limit based Kaplan Meier method.</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="0" upper_limit="71"/>
                    <measurement group_id="O2" value="61" lower_limit="40" upper_limit="82"/>
                    <measurement group_id="O3" value="45" lower_limit="33" upper_limit="57"/>
                    <measurement group_id="O4" value="39" lower_limit="27" upper_limit="51"/>
                    <measurement group_id="O5" value="46" lower_limit="16" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAE= 100 days after transplantation All cause mortality = 12 years</time_frame>
      <desc>SAE= Regimen related toxicity grade 2-4 in any organ system (Bearman Score, range from 0 (none) to 4 (fatal)</desc>
      <group_list>
        <group group_id="E1">
          <title>Acute Leukemia</title>
          <description>Patients diagnosed with and treated for acute myeloid leukemia or acute lymphoblastic leukemia</description>
        </group>
        <group group_id="E2">
          <title>Hodgkin Lymphoma</title>
          <description>Patients diagnosed with and treated for Hodgkin Lymphoma</description>
        </group>
        <group group_id="E3">
          <title>Non-Hodgkin Lymphoma</title>
          <description>Patients diagnosed with and treated for Non-Hodgkin Lymphoma</description>
        </group>
        <group group_id="E4">
          <title>MM/Amyloid</title>
          <description>Patients diagnosed with or treated for multiple myeloma or amyloidosis</description>
        </group>
        <group group_id="E5">
          <title>Solid Tumors</title>
          <description>Patients diagnosed with and treated for a solid tumor</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Bearman Criteria</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Regimen Related Toxicity</sub_title>
                <description>Any organ system (cardiac, renal, pulmonary, lower GI, CNS, hepatic, stomatitis, bladder)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="71"/>
                <counts group_id="E4" events="31" subjects_affected="31" subjects_at_risk="65"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theresa Hahn, PhD</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-5819</phone>
      <email>theresa.hahn@roswellpark.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

